Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Invesco DB Oil Fund (DBO) vs Mesoblast Limited (MESO) Price & Performance

Invesco DB Oil FundTrade
Mesoblast LimitedTrade

Price performance (Past 24H)

Key statistics

Invesco DB Oil Fund vs Mesoblast Limited — how do they compare? Invesco DB Oil Fund trades at $19.83, while Mesoblast Limited trades at $18.01 (market cap $2.12B). Which is the better fit depends on your goals.

DBOMESO
Sector
Commodities - EnergyTechnology
52-Week High
$23.80$20.96
52-Week Low
$11.98$10.96
Market Cap
$2.12B
Enterprise Value
$2.13B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Invesco DB Oil Fund

DBO is trading at $19.59, up 8.47% with strong bullish momentum driven by escalating Middle East tensions that are boosting oil prices. Technical indicators show a bullish trend with support at $19 and resistance at $20, though RSI suggests potential overbought conditions. The stock benefits from geopolitical events that typically drive energy sector performance.

The outlook remains positive as oil price strength translates to potential revenue growth for US energy companies. Key risks include geopolitical volatility and potential supply disruptions. Analyst sentiment appears constructive given the favorable oil market dynamics, though fundamental metrics require verification from recent SEC filings.

Mesoblast Limited

MESO trades at $16.22, up 5.05% today, with a bullish technical outlook from moving averages but mixed oscillators. The company shows strong gross margins of 80.52% but remains unprofitable with a net income margin of -144.33%. Recent news highlights commercial progress, including Ryoncil revenue of $36 million in Q4 2026 and pivotal Phase 3 trial milestones for chronic low back pain.

The outlook is cautiously optimistic, driven by FDA-approved Ryoncil's revenue growth and pipeline advancements, but high valuation (P/S 30.52) and persistent losses pose risks. Analyst consensus leans buy (45.46%), yet investors face volatility from clinical trial outcomes and cash burn concerns.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Invesco DB Oil Fund

DBO provides exposure to WTI crude oil prices through futures contracts. It is designed for investors seeking a way to invest in the performance of the fossil fuel market without purchasing physical oil barrels.

Read more on DBO

About Mesoblast Limited

Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.

Read more on MESO